NCT06891560View on ClinicalTrials.gov

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Adenoid Cystic Carcinoma
Interventions
DRUG

Enfortumab Vedotin

intravenously on Days 1, 8 and 15 of a 28-day cycle

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT06891560 - A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | Biotech Hunter | Biotech Hunter